Examkin

Question

Difficulty: Very hardEndocrine and Metabolic Mechanisms

During morning rounds on the oncology service, a 71-year-old hospitalized individual is found profoundly lethargic and diaphoric. The patient was admitted two days ago for a core needle biopsy of a massive right-sided pleural mass that occupies the lower two-thirds of the hemithorax. Point-of-care capillary blood glucose is 32 mg/dL. A stat venous blood draw is obtained before the administration of intravenous dextrose, which rapidly restores the patient's normal sensorium. The laboratory results from the hypoglycemic episode return as follows:

Plasma glucose: 35 mg/dL
Serum insulin: < 1.0 µU/mL (Normal: 3-25 µU/mL)
Serum C-peptide: 0.1 ng/mL (Normal: 1.1-4.4 ng/mL)
Serum beta-hydroxybutyrate: 0.1 mmol/L (Normal: < 0.4 mmol/L)
Serum growth hormone (GH): < 0.1 ng/mL (Normal: 0.4-10 ng/mL)
Serum insulin-like growth factor 1 (IGF-1): 22 ng/mL (Normal: 70-250 ng/mL)

Which of the following cellular or biochemical mechanisms best explains this patient's clinical presentation and laboratory profile?

  1. Binding of a high-molecular-weight somatomedin to insulin receptors and concurrent suppression of pituitary somatotrophsAnswer
  2. B
    Autonomous exocytosis of zinc-coordinated insulin hexamers from a neuroendocrine neoplasm
  3. C
    Pharmacologic blockade of ATP-sensitive potassium channels causing uninhibited endogenous incretin action
  4. D
    Inherited deficiency of carnitine palmitoyltransferase leading to impaired mitochondrial beta-oxidation
  5. E
    Medication-induced inhibition of hepatic glycogenolysis via antagonism of beta-2 adrenergic receptors

Answer

Binding of a high-molecular-weight somatomedin to insulin receptors and concurrent suppression of pituitary somatotrophs
The correct answer identifies the mechanism of non-islet cell tumor hypoglycemia (NICTH), which classically occurs with large mesenchymal tumors such as solitary fibrous tumors of the pleura (known as Doege-Potter syndrome). These tumors overproduce an incompletely processed form of IGF-2 (a somatomedin) known as 'big IGF-2'. Big IGF-2 binds with high affinity to insulin receptors (specifically the IR-A isoform). This binding mediates profound hypoglycemia and inhibits lipolysis, which explains the inappropriately low beta-hydroxybutyrate (ketone) levels. Furthermore, big IGF-2 crosses the blood-brain barrier and exerts negative feedback on the hypothalamus and pituitary gland, suppressing growth hormone (GH) secretion. The chronically low GH leads to decreased hepatic production of IGF-1 and IGF-binding proteins, further increasing the amount of free, metabolically active big IGF-2 in circulation. This creates the classic laboratory profile seen here: suppressed insulin, C-peptide, ketones, GH, and IGF-1 in the setting of severe fasting hypoglycemia.

Step-by-Step Solution

1
Analyze the basic metabolic state from the labs.
The patient has severe hypoglycemia (35 mg/dL) with undetectable insulin and C-peptide.
This immediately rules out exogenous insulin administration (would have high insulin) and endogenous hyperinsulinism like insulinoma or sulfonylurea use (would have high C-peptide).
2
Evaluate counter-regulatory hormone response and ketone levels.
Beta-hydroxybutyrate is very low (hypoketotic), and GH/IGF-1 are profoundly suppressed.
Normally, non-insulin-mediated hypoglycemia should trigger massive lipolysis (high ketones) and a surge in counter-regulatory hormones like GH. The suppression of lipolysis and GH points to an insulin-like substance acting systemically.
3
Correlate metabolic findings with the clinical presentation (massive pleural mass).
The combination of a large mesenchymal tumor, hypoketotic hypoglycemia, low insulin, and low GH/IGF-1 is diagnostic of non-islet cell tumor hypoglycemia (NICTH), specifically Doege-Potter syndrome.
These tumors secrete incompletely processed Insulin-like Growth Factor 2 (Big IGF-2). Big IGF-2 activates insulin receptors (causing hypoglycemia and preventing ketogenesis) and suppresses pituitary GH secretion (lowering IGF-1).

Key Concept

Pathophysiology of Non-Islet Cell Tumor Hypoglycemia (NICTH) via Big IGF-2
Rate this question

Topics

Endocrine and Metabolic Mechanisms

More questions from this topic